Vyome published research paper on VB 001 Leave-On lotion in BMC Journal.
New Delhi, July 03, 2017: Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, announced publication of research paper on-
"Evaluation of therapeutic potential of VB-001, a leave-on formulation, for treatment of moderate adherent dandruff", in BioMed Central (BMC) Dermatology Journal.
Dandruff is a common scalp condition characterized by excessive scaling and itch. Aberrant colonization of the scalp by commensal Malassezia spp. is a major contributor in the multifactorial etiology of dandruff. Literature based understanding of Malassezia linked pathophysiology of dandruff allowed us to comprehend a strategy to potentiate the efficacy of a known antifungal agent used in dandruff therapy.
The aim of this study was to determine the efficacy and skin safety of VB-001 antidandruff leave-on formulation in comparison with marketed antidandruff ZPTO shampoo in patients with moderate adherent dandruff of the scalp.